By Denny Jacob
Teva Pharmaceuticals said Monday it will pay Rhode Island $21 million over 13 years and provide two treatment options over 10 years after it reached an agreement with the state's Attorney General that settles the state's opioid-related claims.
Under the terms of the settlement, Teva will provide Narcan and Suboxone. Narcan is a nasal spray that can treat narcotic overdose in an emergency situation, while Suboxone can treat narcotic dependence. Teva said the value of the treatments combined is $78.5 million.
Teva said the settlement agreement is not an admission of any liability or wrongdoing. The company added that it continues to actively negotiate a national settlement.
Representatives for Attorney General Peter Neronha didn't immediately return Dow Jones's request for comment.
Teva Pharmaceuticals is a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
03-21-22 1530ET